RxDoctor Payments Data

Hannah Vaughn

Medical · Lakeland, FLNPI 1972045870

Payments from drug & device makers

$2,180in general payments, 2019–2025

Across 79 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$715
  • Sun Pharmaceutical Industries Inc.$290
  • AbbVie$253
  • Incyte Corporation$170
  • Pfizer$101
  • Almirall LLC$80
  • plus $571 from 12 others

What the payments were for

  • Food & beverage$1,84985%
  • Education$33115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,180 in reported general payments places this provider in the 70th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$61,449
Medicare patients
262
Services billed
1,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate18$35,771
Tacrolimus45$5,983
Clobetasol Propionate153$5,675
Pimecrolimus26$5,370
Ketoconazole225$3,683
Fluorouracil33$2,677
Clindamycin Phosphate54$1,407
Betamethasone Dipropionate38$1,297
Triamcinolone Acetonide170$1,110
Ammonium Lactate40$1,090
Fluocinonide22$1,083
Tretinoin11$986
Doxycycline Hyclate52$761
Cephalexin48$517
Fluocinolone AcetonideFluocinolone/Shower Cap16$458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$170$35,77118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,031 medical providers in Florida.

Other medical in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →